Lupin, Neopharmed sign licensing pact for Gastro brand Plasil in Brazil, Philippines
Plasil is widely acknowledged for its efficacy in treating nausea, vomiting, and motility disorders.
Mumbai: Global pharma major Lupin has announced that its subsidiaries Multicare Pharmaceuticals in the Philippines and MedQuimica in Brazil have signed an exclusive licensing agreement with Neopharmed Gentili S.p.A, an Italian pharmaceutical company, for marketing and promotional rights for the Gastroenterology brand, Plasil (metoclopramide), in their respective markets.
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets. Neopharmed will oversee product supply in the Philippines, ensuring quality and compliance with global standards. In Brazil, production will be shifted to Medquimica’s manufacturing facility.
“Our partnership with Neopharmed represents a significant milestone in Lupin’s commitment to expand access to Plasil, one of the most potent anti-emetic treatments, across key emerging markets. Our extensive local presence, regulatory expertise, and strong commercial capabilities in the Philippines and Brazil, together with Neopharmed’s distribution network and reach, will broaden patient access and deliver meaningful health outcomes,” said Fabrice Egros, President of Corporate Development, Lupin.
“We are pleased to partner with Lupin to bring Plasil to two strategic and rapidly growing markets, such as Brazil and the Philippines. This agreement reflects our commitment to expanding Neopharmed’s international footprint, while leveraging Lupin’s strong local presence to ensure that Plasil is available to every patient in need,” said Matteo Meazzini, Director of Business Development, Neopharmed Gentili.
Plasil is widely acknowledged for its efficacy in treating nausea, vomiting, and motility disorders that affect millions of patients.
Read also: Lupin receives positive EMA comittee opinion for eye therapy Ranluspec
Next Story